Compugen
CGEN
#8883
Rank
ยฃ0.10 B
Marketcap
ยฃ1.16
Share price
-4.05%
Change (1 day)
-7.43%
Change (1 year)

P/E ratio for Compugen (CGEN)

P/E ratio as of December 2025 (TTM): -5.13

According to Compugen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.13333. At the end of 2024 the company had a P/E ratio of -9.56.

P/E ratio history for Compugen from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-9.56
2022-1.80-83.26%
2021-10.8-67.16%
2020-32.7141.63%
2019-13.5
2015-16.0-55.89%
2014-36.245.68%
2013-24.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Seagen
SGEN
-57.0 1,011.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-0.0167-99.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
44.9-975.08%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Genetic Technologies
GENE
N/AN/A๐Ÿ‡ฆ๐Ÿ‡บ Australia

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.